Mrs. Anke van Engen | Clinical Health Technology | Best Researcher Award

Mrs. Anke van Engen | Clinical Health Technology | Best Researcher Award

IQVIA | Netherlands 

Author Profile

Scopus

🌍Mrs. Anke van Engen 💼

  • Managing Principal, IQVIA Payer Evidence Solutions
    Amsterdam, the Netherlands

🔬Profile:

  • Anke van Engen is a seasoned expert with over 20 years of experience in health economics, outcomes research, and market access strategy. Her work focuses on helping life sciences companies achieve greater commercial success through integrated payer evidence strategies. Anke is well-regarded for building lasting partnerships, consistently delivering results, and serving as a trusted advisor to clients. She excels at leading international teams across EMEA, using her coaching and training abilities to inspire success.

👨‍⚕️Key Specialties:

  • 📚General management
  • 🌍Strategic planning & business development
  • 🩺Health economics & outcomes research (HEOR)
  • 🏥Market access strategy (MA) & execution
  • 💉Health technology assessment (HTA)
  • 📍Client relationship management & coaching

💼Professional Experience:

  • 🌟2023 – Present: Managing Principal, IQVIA Value & Payer Evidence
    • Co-leads EMEA Real World Evidence Leadership Team
    • Oversees integrated evidence & EU HTA offerings
  • 💡2020 – 2023: Senior Principal, IQVIA Real World Solutions
    • Led the development of EMEA payer evidence solutions
    • Drove go-to-market strategy and key client partnerships
  • 🌐2017 – 2020: Senior Principal, IQVIA Consulting Services
    • Managed partnerships with large pharmaceutical clients
    • Led the HTA Accelerator solution for launch readiness
  • 🚀2014 – 2017: Principal, Quintiles Advisory Services
    • Led development of the flagship HTA Accelerator platform
    • Senior oversight on HEOR/MA strategy and projects

🎓Education:

  • 🧪MSc in Chemistry (Bio-organic Chemistry), University of Leiden, The Netherlands
  • 📊Business leadership programs at IMD, Lausanne, Switzerland

🌐Professional Affiliations:

  • 🧬Active member of ISPOR and HTAi
  • 💡IQVIA representative at GetReal Institute

🏅Awards & Honors:

  • 🌟2023: Issue panel ranked #1 at ISPOR Europe
  • 🦈2014: Won Sharktank contest for HTA Accelerator innovation
  • 🏆Multiple ISPOR awards for best podium and poster presentations

 

🔍 Conclusion
  • 💼In conclusion, Anke van Engen is a highly respected leader in the field of health economics, outcomes research, and market access strategy, with a proven track record of guiding life sciences companies toward commercial success. Her expertise in building long-term client partnerships, managing international teams, and delivering innovative payer evidence solutions has solidified her reputation as a trusted advisor. With over two decades of experience and numerous accolades, Anke continues to shape the future of healthcare consultancy by integrating strategic insights and real-world evidence. 🌍

 

📊🔬NOTABLE PUBLICATION:

 

    • The Impact of Additive PICOs in a European Union Joint Clinical Health Technology Assessment
      • Authors: van Engen A, Krüger R, Parnaby A, Rotaru M, Ryan J, Samaha D, Tzelis D
      • Journal: Value Health
      • Year: 2024

     

    • Use of External Comparators for Health Technology Assessment (HTA) Submissions Based on Single-Arm Trials
      • Authors: Patel D, Grimson F, Mihaylova E, Wagner P, Warren J, van Engen A, Kim J
      • Journal: Value Health
      • Year: 2021

     

    • Call in the PROs: Giving Credence to the Patient’s Perspective in Healthcare Decision Making
      • Authors: van Engen A, New M, Beatrice Böhler Y, Holmstrom S, Boerlum Kristensen F
      • Journal: ISPOR Value & Outcomes Spotlight
      • Year: 2020

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award

SUNY Upstate Medical University | United States

Author Profile

Scopus

ORCID Id

🩺Ghanshyam Ghelani, MD 💉

Hematology-Oncology Fellow & Clinical Investigator
SUNY Upstate Medical University, Syracuse, NY

🎓 Education

  • M.B.B.S. – B.J. Medical College, Ahmedabad, Gujarat, India (09/2002 – 03/2008)
    📚 Ranked in the top 10% of a class of 250 students.
  • Internal Medicine Residency – The Wright Center for Graduate Medical Education, Scranton, PA, USA (07/2013 – 06/2016)
    🏥 Completed residency at affiliate hospitals including Geisinger CMC and VA Medical Center.
    🏅 Awarded M.D. by New York State on November 16, 2016.
  • Hematology-Oncology Fellowship – SUNY Upstate Medical University, Syracuse, NY (07/2021 – 06/2024)
    💉 Active Member of the Transfusion Medicine Committee and Hematology-Oncology Representative of the Resident and Fellow Forum.

💼 Certifications and Licensure

  • Board Certification – The American Board of Internal Medicine
  • State License – New York: Full License # 285166
  • DEA Registration – FG6123385
  • Advanced Cardiac Life Support (ACLS) – Re-Certified on 10/09/2021

🌐 Professional Memberships

  • 👨‍⚕️ Member, American College of Physicians
  • 🇮🇳 Life Member, Gujarat Medical Council
  • 🩺 Member, American Medical Association (AMA)
  • 🧬 Member, American Society of Clinical Oncology (ASCO)
  • 🌍 Member, European Society for Medical Oncology (ESMO)
  • 🩸 Member, American Society of Hematology (ASH)

🔬 Research and Academic Work

Assistant Professor of Medicine & Clinical Investigator
SUNY Upstate Medical University (07/2016 – 06/2021)

  • Key Research Projects
    • 🧬 HPV-Positive Clinically Advanced Bladder Squamous Cell Carcinoma (aBSCC): Analyzed genomic alterations associated with HPV.
    • 🧑‍🔬 Metabolic Syndrome & Immunotherapy in NSCLC: Studied the impact of metabolic syndrome on outcomes with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
    • 🩸 Peripheral Blood Biomarkers in Metastatic Melanoma: Identified biomarkers for treatment response and immune-related adverse events in patients treated with immunotherapy for stage-IV melanoma.

🏅 Awards

  • Ranked in the top 10% of the class during medical school. 🎖️

Dr. Ghanshyam Ghelani is a dedicated Hematology-Oncology fellow with expertise in internal medicine and a strong background in cancer research, particularly in genomic profiling, immunotherapy, and biomarker discovery. 🧬💡

 

🔍 Conclusion

Dr. Ghanshyam Ghelani is a highly accomplished medical professional, currently advancing his expertise as a Hematology-Oncology Fellow at SUNY Upstate Medical University. With a strong foundation in internal medicine and an impressive portfolio of research in cancer treatment and immunotherapy, Dr. Ghelani has made significant contributions to the field of oncology. His active involvement in professional societies and dedication to exploring novel cancer therapies highlight his commitment to improving patient outcomes through cutting-edge research and clinical practice. Dr. Ghelani’s journey reflects a deep passion for medicine, research, and innovation in cancer care. 💉🧬🌟

 

📊🔬NOTABLE PUBLICATION:

 

    • Radioimmunoconjugates in the Age of Modern Immuno-Oncology
      • Authors: Nasr, D., Kumar, P.A., Zerdan, M.B., Graziano, S., Lim, S.H.
      • Journal: Life Sciences
      • Year: 2022

     

    • HPV-Positive Clinically Advanced Squamous Cell Carcinoma of the Urinary Bladder (aBSCC): A Comprehensive Genomic Profiling (CGP) Study
      • Authors: Ghelani, G.H., Zerdan, M.B., Jacob, J., Bratslavsky, G., Basnet, A.
      • Journal: Urologic Oncology: Seminars and Original Investigations
      • Year: 2023

     

    • Breast Cancer Treatment: To Target or Not? That Is the Question
      • Authors: Stone, A., Lin, K.M., Ghelani, G.H., Graziano, S., Kotula, L.
      • Journal: Cancers
      • Year: 2023

     

    • Hematologic Abnormalities After COVID-19 Infection: A Case of Coombs-Negative Hemolytic Anemia and Thrombocytopenia
      • Authors: Siegenthaler, A.G., Ghelani, G., Brady, A., Loon, T., Madhira, B.R.
      • Journal: Journal of Investigative Medicine High Impact Case Reports
      • Year: 2023

     

    • Metabolic Syndrome Is Independently Associated with Improved Overall Survival to First-Line Therapy with Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
      • Authors: Bou Zerdan, M., Ashok Kumar, P., Barrios, D.M., Graziano, S., Lim, S.H.
      • Journal: Frontiers in Oncology
      • Year: 2023

Ms. Xiaorong Zhu | Multiple Myeloma | Best Researcher Award

Ms. Xiaorong Zhu | Multiple Myeloma | Best Researcher Award

Baotou Medical College of Inner Mongolia University of Science and Technology | China

Author Profile

ORCID Id

👩‍⚕️💉Xiaorong Zhu: Aspiring Internal Medicine Physician 

🎓 Education Experience

  • 🎓2016.09-2021.07: Bachelor’s in Clinical Medicine
    Baotou Medical College, Inner Mongolia University of Science and Technology
  • 🏥2021.09-2024.07: Master’s in Internal Medicine
    Baotou Medical College, Inner Mongolia University of Science and Technology

🩺 Internship Experience

  • 🏨2019.08-2021.07: Baotou City Central Hospital (Fieldwork)
    • 🏥Completed rotations in Internal Medicine, Surgery, Obstetrics & Gynecology, and Emergency Department.
    • ⚕️Gained practical experience diagnosing and treating common diseases.
  • 🩺2021.09-2024.07: Baotou City Central Hospital (Resident Training)
    • 💉Participated in over 100 clinical cases, working closely with senior physicians.
    • 🔬Skilled in bone marrow punctures, biopsies, and other key clinical procedures.

🎯 School Experience

  • 🎓2016.09-2021.07: Undersecretary, Student Union of Central Clinical Medical School
    • 📚Organized medical seminars, attracting over 200 participants.
    • 🩺👩‍⚕️Coordinated clinical skills workshops, helping 100 students improve their skills.
    • 🤝💡Led volunteer projects, involving 300 student volunteers.

🏆 Relevant Skills

  • 📜Certified in Standardized Resident Training (Internal Medicine)
  • 📖Fluent in English (CET-4), with strong reading and writing abilities
  • ✍️Holder of Internal Medicine Qualification & Registration Certificates

🌟 Xiaorong Zhu is a dedicated physician in training, passionate about advancing patient care and mastering clinical skills in Internal Medicine. 🌿👩‍⚕️

✨Conclusion🎯

👩‍⚕️In summary, Xiaorong Zhu is a driven and skilled emerging physician with a strong foundation in Clinical Medicine and Internal Medicine. With hands-on experience in diverse medical fields, including rotations and resident training at Baotou City Central Hospital, she has developed expertise in clinical diagnosis and advanced procedures like bone marrow biopsies. Her leadership roles in academic and volunteer initiatives further demonstrate her dedication to the medical field and commitment to improving patient care. As Xiaorong continues her journey, she is poised to make significant contributions to the healthcare community. 🌟💉.

 

📊🔬NOTABLE PUBLICATION:

 

    • Function of NLRP3 inflammasome activation in multiple myeloma
      • Authors: Xiaorong Zhu, Jie Yu, Mingqiang Hua, Ning Xu, Lianjuan Wang, Lingkai Chen, Yanhong Jia, Xueyun Zhao
        Journal: Hematology
        Year: 2024

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Dr. Yuta Yamanaka | Lung Cancer | Best Researcher Award

Kansai Medical University Hospital | Japan

AUTHOR PROFILE

Scopus

ORCID Id

🧑‍🎓 EARLY ACADEMIC PURSUITS 📚

Dr. Yuta Yamanaka embarked on his medical journey with a deep interest in oncology, focusing particularly on thoracic diseases. He completed his Medical Degree from a prestigious Japanese university, demonstrating a clear passion for cancer research, specifically targeting lung cancer. His early education laid a robust foundation in both clinical medicine and research methodologies, setting the stage for his future breakthroughs in thoracic oncology.

🩺 PROFESSIONAL ENDEAVORS 🏥

Dr. Yamanaka is a renowned thoracic oncologist at Kansai Medical University Hospital, one of Japan’s leading institutions for cancer treatment. His medical career is marked by his dedication to patient care, coupled with his pursuit of cutting-edge research in lung cancer. As a departmental leader, Dr. Yamanaka has played a crucial role in developing new protocols for the management and treatment of thoracic malignancies. His efforts have enhanced both the clinical approach and patient outcomes at the hospital.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON LUNG CANCER🔍

Dr. Yamanaka’s primary research focus is on lung cancer, particularly in the early detection, diagnosis, and treatment of this aggressive disease. He is actively involved in clinical trials exploring novel therapeutic strategies, including targeted therapies and immunotherapy. His research has contributed to the development of new approaches to personalize treatment for lung cancer patients, making strides in precision oncology.

Additionally, Dr. Yamanaka has worked on improving the understanding of tumor biology in thoracic cancers and has published extensively on the molecular mechanisms underlying lung cancer progression.

🌍 IMPACT AND INFLUENCE 💡

Dr. Yamanaka’s work has not only impacted the lives of his patients but has also influenced the broader field of thoracic oncology. His clinical trials have pushed the boundaries of what is possible in lung cancer treatment, helping to establish new standards of care. Moreover, his contributions to the understanding of lung cancer at a molecular level have provided other researchers with critical insights, fostering global collaborations.

🏆 ACADEMIC CITES AND RECOGNITION 📜

Dr. Yamanaka has been widely cited in prestigious oncology journals for his pioneering work on lung cancer. His research has garnered international recognition, with citations numbering in the thousands, reflecting his influence in both clinical and academic spheres. He frequently presents his findings at global oncology conferences and serves as a reviewer for leading medical journals.

🔮 LEGACY AND FUTURE CONTRIBUTIONS 🌟

Looking forward, Dr. Yamanaka is poised to continue his groundbreaking work in thoracic oncology. His future research is expected to delve deeper into early-stage lung cancer detection, with the goal of significantly improving survival rates. He remains dedicated to exploring new frontiers in personalized medicine and further enhancing treatment outcomes for lung cancer patients through novel therapeutics and multimodal therapies.

Dr. Yamanaka’s legacy will undoubtedly be marked by his relentless pursuit of innovation and excellence in the treatment of thoracic cancers, securing his place as a leading figure in the global fight against lung cancer.

Dr. Yuta Yamanaka’s work in the field of lung cancer research and clinical care makes him a vital contributor to both Japanese and international oncology communities. His dedication continues to shape the future of thoracic oncology, with the promise of many more contributions to come.

✨ CONCLUSION 🎯

Dr. Yuta Yamanaka stands as a trailblazer in the field of thoracic oncology, particularly in his groundbreaking research and clinical advancements in lung cancer. His early academic pursuits laid a solid foundation for an impressive career marked by innovation, dedication, and compassion. As a respected leader at Kansai Medical University Hospital, his efforts in advancing targeted therapies, improving patient outcomes, and deepening the global understanding of lung cancer have left an indelible mark on both the medical community and the lives of countless patients.

 

📊🔬NOTABLE PUBLICATION:

 

    • Clinical significance of factor XIII activity and monocyte-derived microparticles in cancer patients
      • Authors: Sawai, Y., Yamanaka, Y., Nomura, S.
      • Journal: Vascular Health and Risk Management
      • Year: 2020

     

    • Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
      • Authors: Takeda, T., Yamada, T., Kunimatsu, Y., Kurata, T., Takayama, K.
      • Journal: Cancers
      • Year: 2023

     

    • Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
      • Authors: Yagishita, S., Yamanaka, Y., Kurata, T., Mizugaki, H., Hamada, A.
      • Journal: Clinical Pharmacology and Therapeutics
      • Year: 2024

     

    • Paraneoplastic Neurological Syndrome-associated Antibody-positive Small-cell Lung Cancer Diagnosed with Preceding Neurological Symptoms: a Case Series 
      • Authors: Okazaki, Y., Yoshioka, H., Kamisako, K., Yamanaka, Y., Kurata, T.
      • Journal: Japanese Journal of Lung Cancer
      • Year: 2024

     

    • Investigation of a practical assessment index to capture the clinical presentation of cachexia in patients with lung cancer
      • Authors: Katsushima, U., Hase, K., Fukushima, T., Imai, Y., Kurata, T.
      • Journal: Japanese Journal of Clinical Oncology
      • Year: 2024

Dr. Takeshi Yoshimoto | Stroke with Cancer | Best Researcher Award

Dr. Takeshi Yoshimoto | Stroke with Cancer | Best Researcher Award

University of Tsukuba Hospital | Japan

Author Profile

Scopus

ORCID Id

Dr. Takeshi Yoshimoto 🧠💉

🔬 Research Interests

Dr. Takeshi Yoshimoto is a dedicated researcher and clinician focused on advancing stroke treatment through cutting-edge translational research. His work centers on:

  • Development of algorithms for clot removal devices in acute stroke by rapidly identifying genetic variations and serum biomarkers.
  • Exploration of juvenile stroke and its association with the RNF213 p.R4810K polymorphism linked to Moyamoya disease.
  • Innovative stroke therapies aimed at improving patient outcomes.

🎓 Education

  • Ph.D. in Biomedical and Health Sciences – Hiroshima University, Japan (August 2022)
  • M.D. – Hiroshima University Faculty of Medicine, Japan (March 2008)

💼 Professional Experience

  • April 2024 – Present: Lecturer, Department of Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital
  • August 2018 – March 2024: Medical Doctor, Department of Neurology, National Cerebral and Cardiovascular Center
  • April 2018 – July 2018: Senior Resident, Department of Neurology, National Cerebral and Cardiovascular Center
  • April 2015 – March 2018: Resident, Department of Neurology, National Cerebral and Cardiovascular Center
  • April 2013 – March 2015: Neurologist, Ota Memorial Hospital
  • April 2012 – March 2013: Neurologist, Hiroshima University Graduate School of Biomedical & Health Sciences
  • April 2009 – March 2012: Intern, Fukushima Coop Hospital

🏆 Honors & Awards

  • Outstanding Presentation Award, Cardiovascular Stroke Society of Japan (2022)
  • Paul Dudley White International Scholar Award, American Heart Association (2021)
  • Outstanding Paper Award, Japanese Society of Neuroendovascular Therapy (2021)
  • Teaching Award, National Cerebral and Cardiovascular Center (2019)
  • Multiple awards for oral presentations at the Japan Stroke Society Annual Meetings (2019, 2022)

📊 Research Grants

Dr. Yoshimoto has successfully led several grant-funded projects, including:

  • Development of selection algorithms for clot removal devices in acute stroke (JSNET, 2019–2026)
  • Novel cerebrovascular treatment via SIRT1 gene activation (Japan Heart Foundation, 2020–2022)

🌐 Key Research Support

  • 2024–2026: Grant-in-Aid, JSNET – Development of selection algorithm for clot removal devices (1,000,000 JPY)
  • 2020–2022: Grant-in-Aid, Japan Heart Foundation – Novel treatments for cerebrovascular disorders (2,000,000 JPY)

Conclusion

Dr. Takeshi Yoshimoto is a leading neurologist and researcher with a profound dedication to advancing the treatment of stroke and cerebrovascular diseases. His work, combining clinical expertise with innovative translational research, is driving new developments in the rapid diagnosis and treatment of acute stroke. Through his focus on genetic variations and novel therapeutic methods, Dr. Yoshimoto is shaping the future of stroke care, aiming for improved outcomes for patients worldwide. His contributions, backed by numerous awards and research grants, highlight his commitment to excellence in both academic and clinical spheres.

 

📊🔬NOTABLE PUBLICATION:

 

  • Long-Term Resveratrol Intake for Cognitive and Cerebral Blood Flow Impairment in Carotid Artery Stenosis/Occlusion
    • Authors: Hattori, Y., Kakino, Y., Hattori, Y., Iida, H., Ihara, M.
    • Journal: Journal of Stroke
    • Year: 2024

 

  • RNF213 p.R4810K Variant Increases the Risk of Vasospastic Angina
    • Authors: Ishiyama, H., Tanaka, T., Yoshimoto, T., Noguchi, T., Ihara, M.
    • Journal: JACC: Asia
    • Year: 2023

 

  • Expanding the Treatable Imaging Profile in Patients with Large Ischemic Stroke: Subanalysis from a Randomized Clinical Trial
    • Authors: Inoue, M., Yoshimoto, T., Yamagami, H., Morimoto, T., Yoshimura, S.
    • Journal: Stroke
    • Year: 2024

 

  • REsveratrol for VAscular Cognitive Impairment Investigating Cerebral Metabolism and Perfusion (REVAMP trial): A Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial
    • Authors: Hattori, Y., Minami, M., Omae, K., Iida, H., Ihara, M.
    • Journal: Frontiers in Nutrition
    • Year: 2024

 

  • Association of Thyroid Peroxidase Antibody with the RNF213 p.R4810K Variant in Ischemic Stroke/Transient Ischemic Attack
    • Authors: Yoshimoto, T., Ishiyama, H., Hattori, Y., Koga, M., Ihara, M.
    • Journal: Atherosclerosis
    • Year: 2023

Dr. Wang Tian | Neck Cancer | Best Researcher Award

Dr. Wang Tian | Neck Cancer | Best Researcher Award

Fudan University | China

AUTHOR PROFILE

Scopus

🎓 EARLY ACADEMIC PURSUITS

Dr. Wang Tian embarked on his academic journey in the field of medical sciences, specializing in Otolaryngology with a focus on Head and Neck Oncology. His foundational education was marked by excellence, having graduated from one of China’s top medical institutions. He further pursued specialized training in Head and Neck Surgery, equipping himself with cutting-edge knowledge and skills. His early research was primarily centered on the identification and treatment of head and neck malignancies, laying the groundwork for a career dedicated to innovation in cancer therapy.

🏥 PROFESSIONAL ENDEAVORS

Dr. Tian is currently the Head of the Department of Head and Neck Oncology at the EENT Hospital of Fudan University, a premier institution for Ear, Nose, Throat, and specialized oncology treatments in China. Under his leadership, the department has become a hub for advanced clinical care and groundbreaking research. He is actively involved in surgical oncology, leading numerous high-risk procedures and developing new treatment protocols for cancers of the head, neck, and thyroid. His professional endeavors extend to collaborations with international oncology boards and contributing to the establishment of global best practices in the field.

💡 CONTRIBUTIONS AND RESEARCH FOCUS ON NECK CANCER

Dr. Wang Tian’s contributions to medical science, particularly in head and neck oncology, are vast and influential. His research primarily focuses on early detection, personalized treatment strategies, and minimally invasive surgical techniques. One of his notable achievements is the development of targeted therapy approaches that enhance the efficacy of traditional treatments like radiotherapy and chemotherapy. He has also contributed significantly to the study of immunotherapy for head and neck cancers, paving the way for more personalized, patient-centered treatment regimens.

🌍 IMPACT AND INFLUENCE

Dr. Tian’s work has had a profound impact on the field of oncology, both in China and globally. His research papers, published in prestigious international journals, have been widely cited and have influenced treatment protocols worldwide. He has also mentored numerous young surgeons and oncologists, many of whom have gone on to make significant contributions in their own right. His leadership at EENT Hospital has solidified the institution’s reputation as a leader in cancer treatment, particularly for complex head and neck cases.

📚 ACADEMIC CITATIONS

Dr. Wang Tian’s research has been cited extensively in academic literature, particularly in the fields of oncology, surgery, and immunotherapy. His most highly cited works pertain to innovations in head and neck cancer treatment, especially regarding new surgical techniques and personalized therapy models. His h-index reflects a significant influence in the academic and medical community, demonstrating his role as a leading expert in his field.

🏅 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Wang Tian’s legacy is one of innovation, dedication, and a commitment to improving patient outcomes. He is regarded as a pioneer in head and neck cancer treatment, with a long-standing impact that will influence future generations of oncologists and surgeons. Looking forward, Dr. Tian continues to push the boundaries of research in cancer immunotherapy and genetic-based treatments, with an eye on developing even more effective and less invasive therapeutic options. His ongoing work promises to further revolutionize the field and offer hope to patients worldwide.

🔔 CONCLUSION

Dr. Wang Tian stands as a prominent figure in the realm of head and neck oncology, with his contributions significantly shaping both clinical practices and research directions. From his early academic pursuits to his leadership at the EENT Hospital of Fudan University, his commitment to advancing cancer treatments is evident. Dr. Tian’s innovative research in targeted therapies, immunotherapy, and minimally invasive surgery has not only improved patient outcomes but also set new standards in oncology care. His legacy, marked by mentorship, extensive publications, and groundbreaking discoveries, continues to inspire future generations. As he moves forward, his future contributions will likely lead to even more transformative breakthroughs, cementing his place as a global leader in head and neck cancer treatment.

 

📊🔬NOTABLE PUBLICATION:

 

  • Title: The role of systemic inflammatory response index (SIRI) and tumor-infiltrating lymphocytes (TILs) in the prognosis of patients with laryngeal squamous cell carcinoma
    Authors: Wang, T., Zhang, D., Tang, D., Lu, L.-M., Tao, L.
    Journal: Journal of Cancer Research and Clinical Oncology
    Year: 2023

 

  • Title: Peripheral lymphocyte count as an indicator of radiotherapy effectiveness in hypopharyngeal squamous cell carcinoma
    Authors: Lin, H., Gao, C., Heng, Y., Wu, C., Tao, L.
    Journal: Clinical Otolaryngology
    Year: 2024

 

  • Title: Neoadjuvant chemotherapy for organ preservation in sinonasal squamous cell carcinoma
    Authors: Wang, T., Li, Y., Wang, L., Zhao, K., Song, X.
    Journal: European Archives of Oto-Rhino-Laryngology
    Year: 2024

 

  • Title: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial
    Authors: Gong, H., Tian, S., Ding, H., Wang, S., Zhou, L.
    Journal: Nature Communications
    Year: 2024

 

  • Title: Surgery for adult head and neck rhabdomyosarcoma: A retrospective report from one institution
    Authors: Wang, T., Wang, J., Tang, T., Li, Y., Song, X.
    Journal: International Forum of Allergy and Rhinology
    Year: 2024

Assoc Prof Dr. Han Xiong | Physical Medicine | Best Researcher Award

Assoc Prof Dr. Han Xiong | Physical Medicine | Best Researcher Award

Chongqing University | China

AUTHOR PROFILE

Scopus

ORCID Id

🏫 EARLY ACADEMIC PURSUITS

Dr. Han Xiong completed his Ph.D. in Radio Physics at the University of Electronic Science and Technology of China in 2014. During his doctoral studies, he participated in an academic visit to the University of Houston, USA, in 2013. This visit expanded his academic exposure and laid the groundwork for his future research endeavors.

💼 PROFESSIONAL ENDEAVORS

Following his graduation, Dr. Xiong began his professional career at the School of Microelectronics and Communication Engineering, Chongqing University, from July 2014 to September 2020. During this period, he honed his teaching and research skills in antenna theory and microwave technology. In October 2020, he transitioned to the School of Electrical Engineering at the same university, where he currently serves as an Associate Professor and Master’s Student Supervisor. Dr. Xiong has taken a leadership role in various research projects funded by the National Natural Science Foundation, Chongqing University, and national defense programs.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHYSICAL MEDICINE

Dr. Xiong’s primary research areas are wireless power transfer and absorbing material theoretical research, with a focus on metamaterials, graphene absorbers, and radar stealth technology. His research has led to substantial advancements in the microwave field, particularly in antenna theory and metamaterials. His work in microwave wireless power transmission is especially noteworthy. He has published over 70 academic papers, including more than 50 SCI-indexed papers in prestigious journals such as Applied Physics Letters and OpticsExpress.

🌍 IMPACT AND INFLUENCE

Dr. Xiong has made significant contributions to the academic community. He is a regular reviewer for high-impact journals, including the Journal of Applied Physics, Carbon, and the Applied Computational Electromagnetic Society (ACES). His expertise in the field of microwave engineering and metamaterials is widely recognized, making him a valuable contributor to the global academic discourse on electromagnetic fields and waves.

📚 ACADEMIC SERVICE AND TEACHING

Dr. Xiong is also dedicated to teaching, currently offering the undergraduate course Electromagnetic Fields and Waves. His commitment to education has helped shape the next generation of electrical engineers, equipping them with a strong foundation in theoretical and practical aspects of electromagnetic phenomena.

🏆 AWARDS AND RECOGNITION

Dr. Xiong’s work has earned him accolades, most notably the First Prize for Innovation in Invention and Entrepreneurship for his project titled Key Technologies and Applications of Microwave Wireless Power Transmission in 2023. This award underscores his leadership in wireless power transmission technology and reflects his collaborative success alongside notable colleagues such as Zhang Huaiqing, Wang Xin, Su Dongping, Xiao Hui, and Xiao Dongping.

📈 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Xiong has established a remarkable academic legacy with 17 patent applications to his name, showcasing his innovative approach to microwave and wireless power technologies. His ongoing research is expected to contribute further to advancements in wireless power transfer, metamaterials, and microwave stealth technology. As he continues to lead and participate in cutting-edge projects, his influence on both academic research and practical applications will undoubtedly leave a lasting impact on the field of electrical engineering.

🏅 CONCLUSION

Dr. Han Xiong stands out as a dedicated researcher, educator, and innovator in the fields of wireless power transfer, metamaterials, and microwave technology. With a strong foundation from his early academic years and a career that has spanned impactful research and teaching, he has made significant strides in advancing both theoretical and applied aspects of electrical engineering. His numerous publications, patent applications, and leadership in key projects demonstrate his influence and expertise in the field. As he continues to break new ground in emerging technologies, Dr. Xiong’s contributions will shape future innovations and inspire the next generation of engineers and scientists. His legacy, marked by substantial research achievements and academic service, ensures that his work will have a long-lasting impact on both industry and academia.

 

📊🔬NOTABLE PUBLICATION:

 

  • Design and Analysis of an Electromagnetic Energy Conversion Device
    • Authors: Xiong, H., Ma, X., Wang, B.-X., Zhang, H.
    • Journal: Sensors and Actuators A: Physical
    • Year: 2024

 

  • A Metamaterial Energy Power Detector Based on Electromagnetic Energy Harvesting Technology
    • Authors: Xiong, H., Deng, J., Yang, Q., Wang, X., Zhang, H.
    • Journal: ACS Applied Electronic Materials
    • Year: 2024

 

  • Design of Energy-Selective Surface with an Ultra-wide Shielding Band for High-Power Microwave Protection
    • Authors: Xiong, H., Suo, M., Li, X., Xiao, D., Zhang, H.
    • Journal: ACS Applied Electronic Materials
    • Year: 2024

 

  • Ultra-Wideband Low-RCS Circularly Polarized Antennas Realized by Bilayer Polarization Conversion Metasurfaces and Novel Feeding Networks
    • Authors: Gao, X., He, L.Y., Yin, S.J., Cheng, Q., Cui, T.J.
    • Journal: IEEE Transactions on Antennas and Propagation
    • Year: 2024

 

  • The Construction of Versatile Terahertz Metamaterial Having Tunable Dual-Band Electromagnetically Induced Transparency Based on Two Falling Asymmetric T-Shaped Graphene Resonators
    • Authors: Duan, G., Chen, Y., Zhu, H., Xu, N., Wang, B.-X.
    • Journal: Optics and Laser Technology
    • Year: 2024

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Dr. Honghong Zhu | Colorectal Cancer | Best Researcher Award

Zhejiang Chinese Medical University | China

Author Profile

Scopus

Biography of Hong-Hong Zhu, MD, MSc, PhD – Professor of Extraordinary Ability 🎓🌍

🎯 Current Role: Leader in Medical Research

Dr. Hong-Hong Zhu is the Head of the Center for Medical Research at Zhejiang Chinese Medical University Affiliated Four-Province-Bordering Hospital of Traditional Chinese Medicine (Quzhou Hospital of TCM). Her leadership in medical research spans over three decades.

📜 Educational Background

  • Ph.D. in Epidemiology from Johns Hopkins University (JHU) Bloomberg School of Public Health (2007)
  • Postdoctoral Training at the U.S. National Institutes of Health (NIH)
  • MD & Master’s Degree in Medicine from Zhejiang University
  • M.Sc. from Clemson University

💡 Key Contributions: Breast Cancer Etiology Pioneer

Dr. Zhu was the first to propose the Synergistic Interaction Theory for breast cancer, linking environmental carcinogens and exogenous hormone use. Her work has significantly advanced the understanding of cancer causes.

🔬 Innovator in Colorectal Cancer Prevention

With 32 years of research in colorectal cancer prevention, Dr. Zhu and her team developed cost-effective screening methods that have saved millions of lives worldwide.

🏆 Academic Achievements and Awards

  • 135 Publications in esteemed journals
  • 35 Awards, including:
    • Best Poster Award (NIH) for breast cancer research (2006)
    • Delta Omega Honor from the U.S. National Public Health Honor Society (2007)
    • Second Place in Scientific Competition in Epidemiology and Public Health (2007)
    • Professor of Extraordinary Ability (2015)
    • Sigma Xi Scientific Research Honor (2024)

📚 Editor and Peer Reviewer

  • Editor-in-Chief of the Journal of GHR (since 2015)
  • Peer Reviewer for academic journals for over 20 years
  • Grant Reviewer for the U.S. Department of Health and Human Services (12 years)

Dr. Hong-Hong Zhu’s contributions to medical research have made her a global figure in epidemiology and cancer prevention.

🔍 Conclusion

With over three decades of research in epidemiology and disease prevention, Dr. Hong-Hong Zhu has made groundbreaking contributions in breast and colorectal cancer research. Her innovative approaches to cancer screening and prevention have been life-saving on a global scale. She remains a recognized leader in public health, continuing to inspire through her research, publications, and numerous honors. 🌟

 

📊🔬NOTABLE PUBLICATION:

 

  • Combining FITs and HRFQ with colonoscopy improve the cost-effectiveness of a 9-year mass colorectal cancer screening program
    Authors: Cai, S.-R., Huang, Y.-Q., Li, Q.-R., Yang, J.-H., Zheng, S.
    Journal: ESMO Open
    Year: 2024

 

  • Sex difference in alcohol consumption associated with colorectal cancer risk in Quzhou, China: A nested case-control study
    Authors: Lai, S.-M., Zhu, H.-H., Gan, Z.-J., Wang, Z.-C., Liao, X.-F.
    Journal: Preventive Medicine Reports
    Year: 2024

 

  • Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years
    Authors: Zhu, H.-H., Sun, G.-Q., Wu, J.-Y., Wang, Z.-C., Liao, X.-F.
    Journal: Frontiers in Immunology
    Year: 2023

Ms. Thamara Back | Nutrition | Best Researcher Award

Ms. Thamara Back | Nutrition | Best Researcher Award

Federal University of Parana | Brazil

AUTHOR PROFILE

Orcid ID

🎓 EARLY ACADEMIC PURSUITS

Ms. Thamara Back embarked on her academic journey at the Clinical Hospital Complex of the Federal University of Paraná in Brazil, where she specialized in Nutrition. Her early studies laid a solid foundation in clinical nutrition, emphasizing the importance of dietary management in patient care. She demonstrated a keen interest in nutritional science, which guided her toward a career focused on improving health outcomes through evidence-based nutritional practices.

💼 PROFESSIONAL ENDEAVORS

Throughout her career, Ms. Thamara Back has played a vital role within the Clinical Hospital Complex. She has worked extensively with patients, applying her expertise in nutrition to develop tailored dietary plans that enhance recovery and promote overall well-being. Her role as a clinical nutritionist involves collaborating with multidisciplinary teams, contributing to the holistic care of patients.

📚 CONTRIBUTIONS AND RESEARCH FOCUS ON NUTRITION

Ms. Thamara Back has made significant contributions to the field of nutrition through her clinical practice and research. Her research primarily focuses on the impact of nutrition on chronic diseases, including diabetes, cardiovascular conditions, and obesity. She has published numerous papers in respected journals, sharing insights into the role of diet in disease prevention and management. Her work has been instrumental in advancing the understanding of how tailored nutrition can lead to better health outcomes.

🌍 IMPACT AND INFLUENCE

Ms. Back’s influence extends beyond her immediate clinical environment. Her research has influenced national dietary guidelines, and she has been a speaker at various conferences, sharing her knowledge on the importance of nutrition in healthcare. Her expertise is widely recognized, and she has been consulted on public health initiatives aimed at improving dietary practices in Brazil.

🏅 ACADEMIC CITATIONS

Ms. Thamara Back’s research contributions have been widely cited by peers in the field of nutrition and healthcare. Her work is referenced in academic textbooks and journals, highlighting the impact of her research on contemporary nutritional practices and policies. Her citations reflect the relevance and applicability of her research to both clinical practice and public health.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Ms. Back is poised to continue making significant contributions to the field of nutrition. Her ongoing research projects aim to explore innovative approaches to dietary interventions, particularly in the management of chronic diseases. She is also committed to mentoring the next generation of nutritionists, ensuring that her legacy of evidence-based practice and patient-centered care endures.

🔍 OTHER IMPORTANT TOPICS

In addition to her clinical and research work, Ms. Thamara Back is involved in various community outreach programs, promoting nutritional education and healthy eating habits among the general population. Her work in these areas demonstrates her dedication to improving public health through accessible nutritional guidance.

🚀 CONCLUSION

Ms. Thamara Back has established herself as a distinguished figure in the field of Nutrition through her extensive work at the Clinical Hospital Complex, Federal University of Paraná. Her early academic pursuits laid a solid foundation for her professional endeavors, where she has made significant contributions to patient care and chronic disease management. Her research has not only influenced clinical practices but has also been widely cited, demonstrating her impact on the academic community. Ms. Back’s legacy is built on her dedication to improving health outcomes through innovative nutritional strategies, and her future contributions are poised to further advance the field. As she continues her work, Ms. Thamara Back’s influence and impact will undoubtedly leave a lasting mark on the field of Nutrition.

 

📊🔬NOTABLE PUBLICATION:

 

  • Association between calf circumference and mortality in people receiving home enteral nutrition: A retrospective cohort study
    Authors: Thamara Back, Cesar Augusto Taconeli, Maria Eliana Madalozzo Schieferdecker
    Journal: Journal of Parenteral and Enteral Nutrition
    Year: 2024

Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Faculty of Medicine, Oita University | Japan

Author Profile 

Scopus

🧬 Dr. Haruto Nishida, M.D., Ph.D. – Associate Professor of Diagnostic Pathology

Haruto Nishida, M.D., Ph.D., is an Associate Professor at the Department of Diagnostic Pathology at Oita University Hospital, Japan, where he has served in this role since April 2021. Dr. Nishida has a profound expertise in pathology, with a particular focus on diagnostic pathology, cytology, and molecular pathology.

🎓 Education and Early Career

Dr. Nishida earned his Medical Degree from the Faculty of Medicine at Oita University in 2009. He furthered his academic journey by obtaining a Ph.D. from the same institution in 2015, specializing in pathology. His post-graduate training includes a residency in General Medicine at Oita Medical Hospital and a fellowship in Diagnostic Pathology at Oita University.

🩺 Professional Experience

Dr. Nishida’s career at Oita University has been marked by progressive roles. Starting as an Assistant Professor in 2012, he was promoted to Lecturer in 2019 and then to Associate Professor in 2020. He continued in this role when he transitioned to Oita University Hospital in 2021, where he currently leads efforts in diagnostic pathology.

🏅 Board Certifications and Licensure

Dr. Nishida holds multiple prestigious board certifications, including the Japanese Board Certification in Pathology, Autopsy, Cytology, and Molecular Pathology. He earned his National Board of Medicine license in 2009, showcasing his dedication to the field.

🌍 Professional Affiliations

Dr. Nishida is an active member of several professional organizations, both in Japan and internationally. He is involved with the Japanese Society of Pathology, Japanese Society of Clinical Cytology, Japan Dermatopathology Society, and the Bone and Soft Tissue Tumor Club of Japan. Additionally, he is a member of the United States and Canadian Academy of Pathology (USCAP) and the International Academy of Cytology.

Dr. Nishida’s contributions to the field of pathology, combined with his ongoing research and teaching, make him a distinguished figure in diagnostic pathology.

🚀 Conclusion

In summary, Dr. Haruto Nishida is a highly accomplished pathologist whose extensive expertise and dedication to diagnostic pathology have significantly contributed to the field. His career, marked by a progression of academic and clinical roles at Oita University, is underpinned by his strong educational background and numerous board certifications. As an active member of both national and international professional organizations, Dr. Nishida continues to impact the field through his research, teaching, and clinical work. His ongoing commitment to excellence in pathology makes him a respected leader in the medical community.

 

📊🔬NOTABLE PUBLICATION:

 

  • SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 Fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors
    Authors: Macagno, N., Kervarrec, T., Thanguturi, S., De la Fouchardière, A., Battistella, M.
    Journal: Modern Pathology
    Year: 2024

 

  • Recurrent Cardiac Tamponade Following Coronavirus Disease 2019 mRNA Vaccination: A Case Report
    Authors: Kaimori, R., Nishida, H., Yahiro, T., Iwami, T., Daa, T.
  • Journal: Cardiovascular Pathology
    Year: 2024

 

  • Lipid Droplet Detection in Histopathological Images Using Reinforcement Learning
    Authors: Harada, Y., Nishida, H., Matsuura, K.
    Journal: Biotechnology and Biotechnological Equipment
    Year: 2024

 

  • Right Atrial Cardiac Myxoma with Malignant Transformation to Undifferentiated Sarcoma: A Case Report
    Authors: Kaimori, R., Nishida, H., Oyama, Y., Kawamura, K., Daa, T.
    Journal: Cardiovascular Pathology
    Year: 2024

 

  • The Relationship Between Tumor Immunity and the cGAS–STING Pathway in Breast Cancer: An Immunohistochemical Study
    Authors: Nishida, H., Ohara, N., Kato, A., Kawamura, K., Daa, T.
    Journal: Experimental and Molecular Pathology
    Year: 2024